These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6177950)

  • 21. Inotropic drugs and their mechanisms of action.
    Scholz H
    J Am Coll Cardiol; 1984 Aug; 4(2):389-97. PubMed ID: 6330195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.
    Harrison SA; Reifsnyder DH; Gallis B; Cadd GG; Beavo JA
    Mol Pharmacol; 1986 May; 29(5):506-14. PubMed ID: 3010079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inotropic effects of amrinone and milrinone on contraction and relaxation of isolated cardiac muscle.
    Sys SU; Goenen MJ; Chalant CH; Brutsaert DL
    Circulation; 1986 Mar; 73(3 Pt 2):III25-35. PubMed ID: 3002662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcellular distribution of high-affinity type IV cyclic AMP phosphodiesterase activity in rabbit ventricular myocardium: relations to the effects of cardiotonic drugs.
    Kithas PA; Artman M; Thompson WJ; Strada SJ
    Circ Res; 1988 Apr; 62(4):782-9. PubMed ID: 2832097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential sensitivity to cardiotonic drugs of cyclic AMP phosphodiesterases isolated from canine ventricular and sinoatrial-enriched tissues.
    Komas N; Lugnier C; Le Bec A; Serradeil-Le Gal C; Barthélémy G; Stoclet JC
    J Cardiovasc Pharmacol; 1989 Aug; 14(2):213-20. PubMed ID: 2476593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
    Lavan BE; Lakey T; Houslay MD
    Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of cyclic AMP in the direct inotropic action of amrinone. Biochemical and functional evidence.
    Honerjäger P; Schäfer-Korting M; Reiter M
    Naunyn Schmiedebergs Arch Pharmacol; 1981 Dec; 318(2):112-20. PubMed ID: 6276787
    [No Abstract]   [Full Text] [Related]  

  • 28. Molecular basis for the cardiovascular activities of amrinone and AR-L57.
    Hayes JS; Bowling N; Boder GB; Kauffman R
    J Pharmacol Exp Ther; 1984 Jul; 230(1):124-32. PubMed ID: 6086873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization and pharmacological relevance of high affinity binding sites for [3H]LY186126, a cardiotonic phosphodiesterase inhibitor, in canine cardiac membranes.
    Kauffman RF; Utterback BG; Robertson DW
    Circ Res; 1989 Jul; 65(1):154-63. PubMed ID: 2544318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of amrinone, a cardiotonic drug, on calcium movements in dog erythrocytes.
    Parker JC; Harper JR
    J Clin Invest; 1980 Aug; 66(2):254-9. PubMed ID: 7400314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of cyclic AMP-dependent protein kinase activity by the cardiotonic drugs amrinone and milrinone.
    Earl CQ; Linden J; Weglicki WB
    Life Sci; 1986 Nov; 39(20):1901-8. PubMed ID: 2430162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In contrast to forskolin and 3-isobutyl-1-methylxanthine, amrinone stimulates the cardiac voltage-sensitive release mechanism without increasing calcium-induced calcium release.
    Xiong W; Moore HM; Howlett SE; Ferrier GR
    J Pharmacol Exp Ther; 2001 Sep; 298(3):954-63. PubMed ID: 11504790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological and biochemical effects of the cardiotonic agent Org10325 in isolated cardiac and vascular tissue preparations.
    Shahid M; Martorana MG; Cottney JE; Marshall RJ
    Br J Pharmacol; 1990 Aug; 100(4):735-42. PubMed ID: 2169938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of sulmazole (AR-L 115 BS) on contractile force and cyclic AMP levels in canine ventricular muscle: comparison with MDL 17,043.
    Endoh M; Yanagisawa T; Morita T; Taira N
    J Pharmacol Exp Ther; 1985 Jul; 234(1):267-73. PubMed ID: 2989507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective inhibition of cyclic AMP phosphodiesterase from various human tissues by milrinone, a potent cardiac bipyridine.
    Ito M; Tanaka T; Saitoh M; Masuoka H; Nakano T; Hidaka H
    Biochem Pharmacol; 1988 May; 37(10):2041-4. PubMed ID: 2837222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology of the bipyridines: amrinone and milrinone.
    Alousi AA; Johnson DC
    Circulation; 1986 Mar; 73(3 Pt 2):III10-24. PubMed ID: 2417744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of amrinone on sodium-calcium exchange in cardiac sarcolemmal vesicles.
    Mallov S
    Res Commun Chem Pathol Pharmacol; 1983 Aug; 41(2):197-210. PubMed ID: 6635316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
    Eckly AE; Lugnier C
    Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.
    Torphy TJ; Cieslinski LB
    Mol Pharmacol; 1990 Feb; 37(2):206-14. PubMed ID: 2154670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of amrinone and enoximone on the subclasses of cyclic AMP phosphodiesterase from human heart and kidney.
    Masuoka H; Ito M; Nakano T; Naka M; Tanaka T
    J Cardiovasc Pharmacol; 1990 Feb; 15(2):302-7. PubMed ID: 1689427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.